Fulcrum Therapeutics (FULC) Cash from Investing Activities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Cash from Investing Activities data on record, last reported at -$128.2 million in Q1 2026.

  • On a quarterly basis, Cash from Investing Activities fell 16400.64% to -$128.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$96.7 million, a 1348.9% decrease, with the full-year FY2025 number at $30.7 million, down 4.69% from a year prior.
  • Cash from Investing Activities reached -$128.2 million in Q1 2026 per FULC's latest filing, down from -$1.0 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for FULC hit a ceiling of $38.1 million in Q1 2024 and a floor of -$128.2 million in Q1 2026.
  • A 5-year average of -$5.3 million and a median of $4.4 million in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 934.58% in 2023, then plummeted 16400.64% in 2026.
  • Tracing FULC's Cash from Investing Activities over 5 years: stood at -$36.4 million in 2022, then soared by 150.48% to $18.4 million in 2023, then plummeted by 87.69% to $2.3 million in 2024, then plummeted by 146.42% to -$1.0 million in 2025, then plummeted by 12122.12% to -$128.2 million in 2026.
  • Business Quant data shows Cash from Investing Activities for FULC at -$128.2 million in Q1 2026, -$1.0 million in Q4 2025, and $18.6 million in Q3 2025.